Abstract
Breast cancer is a heterogeneous disorder with different molecular subtypes and biological characteristics for which there are diverse therapeutic approaches and clinical outcomes specific to any molecular subtype. It is a global health concern due to a lack of efficient therapy regimens that might be used for all disease subtypes. Therefore, treatment customization for each patient depending on molecular characteristics should be considered. Precision medicine for breast cancer is an approach to diagnosis, treatment, and prevention of the disease that takes into consideration the patient’s genetic makeup. Precision medicine provides the promise of highly individualized treatment, in which each individual breast cancer patient receives the most appropriate diagnostics and targeted therapies based on the genetic profile of cancer. The knowledge about the molecular features and development of breast cancer treatment approaches has increased, which led to the development of new targeted therapeutics. Tumor genomic profiling is the standard of care for breast cancer that could contribute to taking steps to better management of malignancies. It holds great promise for accurate prognostication, prediction of response to common systemic therapies, and individualized monitoring of the disease. The emergence of targeted treatment has significantly enhanced the survival of patients with breast cancer and contributed to reducing the economic costs of the health system. In this review, we summarized the therapeutic approaches associated with the molecular classification of breast cancer to help the best treatment selection specific to the target patient.
Similar content being viewed by others
References
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698–707
Bradbury AR, Olopade OI (2007) Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 8(3):255–267
Kim H, Choi DH (2013) Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. J breast cancer 16(4):357
Skol AD, Sasaki MM, Onel K (2016) The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance. Breast Cancer Res 18(1):1–8
Rizzolo P, Silvestri V, Falchetti M, Ottini L (2011) Inherited and acquired alterations in development of breast cancer. Appl Clin Genet 4:145
Godet I, Gilkes DM (2017) BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 4(1)
Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73(3):643–651
American Cancer Society Breast Cancer. https://www.cancerorg/cancer/breast-cancerhtml
World Health Organization (WHO) (2020) Breast cancer. https://wwww.hoint/cancer/prevention/diagnosis-screening/breast-cancer/en/
Toss T, Cristofanilli A M (2015) Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 17(1):1–11
Polyak K (2011) Heterogeneity in breast cancer. J Clin Investig 121(10):3786–3788
Apostolou P, Fostira F (2013) Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013; 2013:747318
Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4(3):174–191
Godet I, Gilkes DM (2017) BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 4(1). https://doi.org/10.15761/ICST.1000228
Daniyal A, Santoso I, Gunawan NHP, Barliana MI, Abdulah R (2021) Genetic Influences in Breast Cancer Drug Resistance. Breast Cancer 13:59–85
Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F et al (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 273(7):535–541
Han Y, Yu X, Li S, Tian Y, Liu C (2020) New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Front Oncol 25:10:578095
Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R et al (2019) Hereditary breast cancer; Genetic penetrance and current status with BRCA. J Cell Physiol 234(5):5741–5750
Mehrgou A, Akouchekian M (2016) The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran 15:30:369
Shiovitz S, Korde LA (2015) Genetics of breast cancer: a topic in evolution. Ann Oncol 26(7):1291–1299
Kaur RP, Vasudeva K, Kumar R, Munshi A (2018) Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Curr Pharm Des 24(30):3566–3575
Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4(2):1–7
Duffy MJ, Synnott NC, Crown J (2018) Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat 170(2):213–219
Kaur RP, Vasudeva K, Kumar R, Munshi AJCpd (2018) Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Curr Pharm Des 24(30):3566–3575
Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF (2013) PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett 6(1):161–168
Chang S-H, Moon B-I, Suh H-S, Sung S-H, Han W-S, Cho M-S et al (2005) Loss of PTEN expression in breast cancers. Korean J Pathol 39(4):236–241
Alkaf A, Al-Jafari A, Wani TA, Alqattan S, Zargar S (2017) Expression of STK11 gene and its promoter activity in MCF control and cancer cells. Biotech 7(6):1–5
Zubair M, Wang S, Ali N (2021) Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol 26:11:632079
Ahmed M, Rahman N (2006) ATM and breast cancer susceptibility. Oncogene 25(43):5906–5911
De Jong M, Nolte I, Te Meerman G, Van der Graaf W, Oosterwijk J, Kleibeuker J et al (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39(4):225–242
Biancolella M, Testa B, Salehi LB, D’Apice MR, Novelli G (2020) Genetics and Genomics of Breast Cancer: update and translational perspectives. Seminars in cancer biology. Elsevier
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X et al (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47–54
Board PCGE (2020) Cancer Genetics Risk Assessment and Counseling (PDQ®). PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US)
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 68(6):394–424
Vieira AF, Schmitt F (2018) An update on breast cancer multigene prognostic tests—emergent clinical biomarkers. Front Med (Lausanne) 4:5:248
Kittaneh M, Montero AJ, Glück S (2013) Molecular profiling for breast cancer: a comprehensive review. Biomarkers Cancer 5:61–70
Fekih M, Petit T, Zarca D, Guinebretière J-M, André F, Pierga J-Y et al (2014) Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey. Bull Cancer 101(10):918–924
Fekih M, Petit T, Zarca D, Guinebretière J-M, André F, Pierga J-Y et al (2014) Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey. Bull Cancer 101(10):919
Assi H, Bou Zerdan M, Ibrahim M, El Nakib C, Hajjar R (2020) Genomic Assays in Node Positive Breast Cancer Patients: A Review. Front Oncol 10:3461
Slodkowska EA, Ross JS (2009) MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 9(5):417–422
Van’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536
Chia S (2018) Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date. Curr Oncol 25(s1):125–130
Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA et al (2012) A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 133:37–47
Mittempergher L, Delahaye LJ, Witteveen AT, Snel MH, Mee S, Chan BY et al (2020) Performance characteristics of the BluePrint® breast cancer diagnostic test. Transl Oncol 13:100756
Viale G, Hanlon Newell AE, Walker E, Harlow G, Bai I, Russo L et al (2019) Ki-67 (30 – 9) scoring and differentiation of Luminal A-and Luminal B-like breast cancer subtypes. Breast Cancer Res Treat 178:451–458
Bou Zerdan M, Ibrahim M, Nakib CE, Hajjar R, Assi HI (2020) Genomic Assays in Node Positive Breast Cancer Patients: A Review. Front Oncol 10:609100
Ovcaricek T, Takac I, Matos E (2019) Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer. Radiol Oncol 53(3):285
Warf MB, Rajamani S, Krappmann K, Doedt J, Cassiano J, Brown K et al (2017) Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer. Future Sci OA 3(3):FSO221
Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R (2017) Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information? Eur J Surg Oncol 43(5):909–920
Fayanju OM, Park KU, Lucci A (2018) Molecular genomic testing for breast cancer: utility for surgeons. Ann Surg Oncol 25(2):512–519
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):1–11
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C et al (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4(4):545–553
Corsinovi D, Usai A, Sarlo M, Giannaccini M, Ori M (2021) Zebrafish Avatar to Develop Precision Breast Cancer Therapies. Anti-cancer Agents Med Chem 22(4):748–759
Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Thennavan A, Beca F, Xia Y, Garcia-Recio S, Allison K, Collins LC et al (2021) Molecular analysis of TCGA breast cancer histologic types. Cell Genomics 1(3):100067
do Nascimento RG, Otoni KM (2020) Histological and molecular classification of breast cancer: what do we know? Mastology 30:1–8
Tsang J, Tse GM (2020) Molecular classification of breast cancer. Adv Anat Pathol 27(1):27–35
Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR (2014) Molecular classification of breast cancer. Virchows Arch 465(1):1–14
Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9(1):16–32
Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G et al (2018) Triple negative breast cancer in Asia: An insider’s view. Cancer Treat Rev 62:29–38
Yin L, Duan J-J, Bian X-W, Yu S-c (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):1–13
Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncol (Williston Park NY) 22(11):1233
Hossain F, Majumder S, David J, Miele L (2021) Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. Cancers 13(15):3739
Fan W, Chang J, Fu P (2015) Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem 7(12):1511–1519
Costa B, Amorim I, Gärtner F, Vale N (2020) Understanding breast cancer: From conventional therapies to repurposed drugs. Eur J Pharm Sci 151:105401
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA et al (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438
Zimmer AS, Gillard M, Lipkowitz S, Lee J-M (2018) Update on PARP inhibitors in breast cancer. Curr Treat Options Oncol 19(5):1–19
Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JH, Swen JJ et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210–216
Biancolella M, Testa B, Salehi LB, D’Apice MR, Novelli G Genetics and Genomics of Breast Cancer: update and translational perspectives.Semin Cancer Biol 72:27–35
Ayoub J, Verma S, Verma S (2012) Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol 19(2):91–105
Ma CX, Sparano JA (2019) Treatment approach to metastatic hormone receptor-positive, HER2-negative breast cancer: endocrine therapy and targeted agents. UpToDate, Waltham, MA
Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D’Auria G et al (2021) CDK4/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future perspectives. Cancers 13(2):332
Dean L (2019) Tamoxifen therapy and CYP2D6 genotype. Medical Genetics Summaries[updated 2019 May 1]
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med 380(20):1929–1940
Piccart M, Hortobagyi GN, Campone M, Pritchard K, Lebrun F, Ito Y et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357–2362
Hare S (2018) The Development and Characterisation of Everolimus Resistant Breast Cancer Cells. Brunel University London
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
De Abreu F, Schwartz G, Wells W, Tsongalis G (2014) Personalized therapy for breast cancer. Clin Genet 86(1):62–67
Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E (2020) HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev 88:102033
Kreutzfeldt J, Rozeboom B, Dey N, De P (2020) The trastuzumab era: current and upcoming targeted HER2 + breast cancer therapies. Am J Cancer Res 10(4):1045
Oh D-Y, Bang Y-J (2020) HER2-targeted therapies—a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33–48
Gradishar W, Salerno KE (2016) NCCN guidelines update: breast cancer. J Natl Compr Cancer Netw 14(5S):641–644
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer 2020. http://www.nccnorg/
Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131
Steenbruggen T, Bouwer N, Smorenburg C, Rier H, Jager A, Beelen K et al (2019) Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab? Breast Cancer Res Treat 178(3):597–605
Choong GM, Cullen GD, O’Sullivan CC (2020) Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA. Cancer J Clin 70(5):355–374
Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15(9):924
Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F et al (2014) Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). J Chemother 26(5):300–305
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92(4):414–417
Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A et al (2019) PD-1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol 234(10):16824–16837
Caparica R, Lambertini M, de Azambuja E (2019) How I treat metastatic triple-negative breast cancer. ESMO open 4(Suppl 2):e000504
Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95(11):866–871
Ledermann JA (2016) PARP inhibitors in ovarian cancer. Ann Oncol 27(Suppl 1):i40–i44
Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR et al (2017) A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clin Cancer Res 23(15):4095–4106
de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S et al (2017) Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov 7(6):620–629
Kim DS, Camacho CV, Kraus WL (2021) Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 53(1):42–51
Slade D (2020) PARP and PARG inhibitors in cancer treatment. Gene Dev 34(5–6):360–394
Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T et al (2015) FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy. Clin Cancer Res 21(19):4257–4261
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18(1):75–87
Vagia E, Mahalingam D, Cristofanilli M (2020) The landscape of targeted therapies in TNBC. Cancers 12(4):916
Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK (2015) Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci 36(12):822–846
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F et al (2018) 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 29(8):1634–1657
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K et al (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914–923
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
NS conceptualization and drawing of hypothesis for the study and writing the manuscript in collaboration with MG, SFH, AND SHH. FR provided guidance to the research. MH contributed substantially in study design, manuscript writing, editing.
Corresponding authors
Ethics declarations
Conflict of interest
The authors do not have any financial or non-financial conflict of interest.
Informed consent
All the authors declare their consent for publication.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sarhangi, N., Hajjari, S., Heydari, S.F. et al. Breast cancer in the era of precision medicine. Mol Biol Rep 49, 10023–10037 (2022). https://doi.org/10.1007/s11033-022-07571-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-022-07571-2